Loading...
•
Mar 31, 2020
Ligand Q1 2020 Earnings Report
Reported strong first quarter financial results driven by Captisol sales and raised 2020 financial guidance.
Key Takeaways
Ligand Pharmaceuticals reported first quarter financial results with total revenues of $33.2 million, driven by strong Captisol sales, and raised its 2020 financial guidance to approximately $140 million in total revenues and $3.65 diluted EPS.
First quarter revenues were $33.2 million, compared to $43.5 million for the same period in 2019.
Captisol sales were $21.1 million, up from $9.0 million in the prior year, driven by sales for remdesivir.
Net loss was $(24.1) million, or $(1.46) per diluted share, compared to net income of $666.3 million, or $31.32 per diluted share, for the same period in 2019.
Ligand is raising its 2020 financial guidance to approximately $140 million in total revenues and diluted EPS to be $3.65.
Revenue by Segment
Forward Guidance
Ligand is raising its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $140 million and diluted EPS to be $3.65.
Positive Outlook
- Higher sales of Captisol
Challenges Ahead
- Reductions in royalties
- Reductions in contract revenue
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...